Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer.
Ovarian cancer
Vigil
checkpoint inhibitor
durvalumab
triple-negative breast cancer
Journal
Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
02
2022
accepted:
14
06
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of furin and downstream TGF-β1 and TGF-β2. Vigil has suggested survival benefit in frontline maintenance ovarian cancer patients who are BRCA-wt. In addition, Vigil demonstrates relapse-free and overall survival advantage in homologous recombination-proficient patients with OC. Further evidence of clinical benefit and safety has been demonstrated in combination with atezolizumab. In this pilot study (NCT02725489), the concurrent combination of the programmed death-ligand 1 (PD-L1) inhibitor durvalumab and Vigil was explored in advanced BRCA-wt relapsed triple-negative breast cancer (TNBC) patients and stage III-IV recurrent/refractory OC patients. Patients received the combination regimen of Vigil (1 × 10e6-10e7 cells/dose intradermally, up to 12 doses) and durvalumab (1500 mg/dose intravenous infusion, up to 12 months) once every 4 weeks. The primary objective was to evaluate safety of this combination. The study included 13 BRCA-wt patients (TNBC, n = 8; OC, n = 5). The most common treatment-emergent adverse events (⩾20%) in all patients included injection-site reaction (92.3%), myalgia (38.5%), bruise at injection site (23.1%), and pruritus (23.1%). Three grade 3 treatment-related adverse events were observed and related to durvalumab. There were no grade 4/5 treatment-related adverse events. Median progression-free survival was 7.1 months and the median overall survival was not reached. Prolonged progression-free survival was improved in patients with PD-L1+ tumors (n = 8, hazard ratio = 0.304, 95% confidence interval, 0.0593-1.56, 1-sided Vigil plus durvalumab was well tolerated and showed promising clinical activity in advanced BRCA-wt TNBC and stage III-IV recurrent/refractory OC patients.
Sections du résumé
Background
UNASSIGNED
Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of furin and downstream TGF-β1 and TGF-β2. Vigil has suggested survival benefit in frontline maintenance ovarian cancer patients who are BRCA-wt. In addition, Vigil demonstrates relapse-free and overall survival advantage in homologous recombination-proficient patients with OC. Further evidence of clinical benefit and safety has been demonstrated in combination with atezolizumab.
Methods
UNASSIGNED
In this pilot study (NCT02725489), the concurrent combination of the programmed death-ligand 1 (PD-L1) inhibitor durvalumab and Vigil was explored in advanced BRCA-wt relapsed triple-negative breast cancer (TNBC) patients and stage III-IV recurrent/refractory OC patients. Patients received the combination regimen of Vigil (1 × 10e6-10e7 cells/dose intradermally, up to 12 doses) and durvalumab (1500 mg/dose intravenous infusion, up to 12 months) once every 4 weeks. The primary objective was to evaluate safety of this combination. The study included 13 BRCA-wt patients (TNBC, n = 8; OC, n = 5).
Results
UNASSIGNED
The most common treatment-emergent adverse events (⩾20%) in all patients included injection-site reaction (92.3%), myalgia (38.5%), bruise at injection site (23.1%), and pruritus (23.1%). Three grade 3 treatment-related adverse events were observed and related to durvalumab. There were no grade 4/5 treatment-related adverse events. Median progression-free survival was 7.1 months and the median overall survival was not reached. Prolonged progression-free survival was improved in patients with PD-L1+ tumors (n = 8, hazard ratio = 0.304, 95% confidence interval, 0.0593-1.56, 1-sided
Conclusions
UNASSIGNED
Vigil plus durvalumab was well tolerated and showed promising clinical activity in advanced BRCA-wt TNBC and stage III-IV recurrent/refractory OC patients.
Identifiants
pubmed: 35957960
doi: 10.1177/11795549221110501
pii: 10.1177_11795549221110501
pmc: PMC9358582
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11795549221110501Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Clin Cancer Res. 2011 Mar 1;17(5):1082-9
pubmed: 21233401
Oncoimmunology. 2019 Sep 2;8(11):1652539
pubmed: 31646082
Gynecol Oncol Res Pract. 2017 Sep 07;4:13
pubmed: 28904804
J Transl Med. 2013 Apr 04;11:89
pubmed: 23557194
J Clin Oncol. 2007 Oct 1;25(28):4466-71
pubmed: 17906207
Annu Rev Med. 2019 Jan 27;70:409-424
pubmed: 30379596
JAMA Oncol. 2019 Aug 01;5(8):1132-1140
pubmed: 31194225
Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10
pubmed: 10883018
Clin Adv Hematol Oncol. 2020 Oct;18(10):647-655
pubmed: 33201871
Oncotarget. 2017 Jan 10;8(2):2171-2186
pubmed: 27974689
Br J Cancer. 2015 Apr 28;112(9):1501-9
pubmed: 25867264
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186
pubmed: 28338569
Gynecol Oncol. 2021 Jun;161(3):676-680
pubmed: 33715892
Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235
pubmed: 29402697
Breast Care (Basel). 2016 Dec;11(6):385-390
pubmed: 28228704
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Biosystems. 2021 Apr;202:104341
pubmed: 33482276
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Breast Cancer Res Treat. 2011 Nov;130(1):145-53
pubmed: 21830012
Clin Cancer Res. 2020 Aug 15;26(16):4268-4279
pubmed: 32398324
Eur J Cancer. 2009 Sep;45 Suppl 1:27-40
pubmed: 19775602
J Cancer. 2018 Feb 16;9(5):872-879
pubmed: 29581765
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
JAMA. 2011 Oct 12;306(14):1557-65
pubmed: 21990299
BMJ. 2000 Sep 9;321(7261):624-8
pubmed: 10977847
Cancer Gene Ther. 2022 Jul;29(7):993-1000
pubmed: 34785763
Breast Cancer Res Treat. 2012 Dec;136(3):795-804
pubmed: 23124476
Int J Mol Sci. 2016 Jul 20;17(7):
pubmed: 27447625
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Gynecol Oncol Rep. 2020 Sep 17;34:100648
pubmed: 33364285
Development. 1998 Dec;125(24):4863-76
pubmed: 9811571
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Breast Cancer (Auckl). 2016 Mar 22;10:25-36
pubmed: 27042088
J Ovarian Res. 2019 May 7;12(1):40
pubmed: 31064392
Lancet Oncol. 2021 Sep;22(9):1275-1289
pubmed: 34363762
Ann Oncol. 2015 Jul;26(7):1488-93
pubmed: 25897014
Lancet Oncol. 2020 Dec;21(12):1661-1672
pubmed: 33271095
Mol Ther. 2012 Mar;20(3):679-86
pubmed: 22186789
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
Front Oncol. 2021 May 19;11:648139
pubmed: 34094935
Lancet Oncol. 2020 Sep;21(9):1155-1164
pubmed: 32771088
Gynecol Oncol. 2016 Dec;143(3):504-510
pubmed: 27678295
Oncology. 2014;87(1):21-9
pubmed: 24968881
Ann Surg Oncol. 2013 Oct;20(10):3254-8
pubmed: 23975317
Nat Immunol. 2012 Feb 12;13(3):223-228
pubmed: 22327569
Am J Hum Genet. 2001 Mar;68(3):700-10
pubmed: 11179017
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
Vaccines (Basel). 2016 Nov 03;4(4):
pubmed: 27827885
Cancer Gene Ther. 2022 Mar;29(3-4):369-382
pubmed: 33753870
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Vaccines (Basel). 2021 Aug 12;9(8):
pubmed: 34452019
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
JAMA. 2021 Jan 5;325(1):50-58
pubmed: 33300950
Radiology. 2019 Jun;291(3):554-569
pubmed: 31038410
Mol Ther. 2015 Jun;23(6):1103-1109
pubmed: 25917459